DTIC-DOME
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DTIC-DOME (dacarbazine) is a small-molecule alkylating agent approved in 1975 for injection. It is primarily used in oncology, including treatment of melanoma and lymphomas. The drug works by alkylating DNA, disrupting cancer cell growth and replication.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect smaller team focus on retention and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DTIC-DOME offers limited career growth opportunity; current linked job count is zero, reflecting the product's mature, LOE-approaching status. Roles available focus on defending market share, managing healthcare provider relationships, and preparing for generic competition rather than innovation or market expansion.
Brand ManagerSales Representative (Specialty/Hospital)
Worked on DTIC-DOME at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.